Evidence map›Paper›PMID 39663713›Full record

ArticleCancer2025

Cognitive impairment in patients with melanoma before adjuvant immune checkpoint inhibitor therapy and associations with brain gray matter, catechol-O-methyltransferase genotype, and psychological factors.

Josefine T Danielsen, Robert Zachariae, Henrik Schmidt, Jesper F Kallehauge, Julie K Thomadsen, Jeffrey S Wefel, Lisa M Wu, Ali Amidi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Long-term cognitive function after treatment with immune checkpoint inhibition for melanoma.Journal of cancer survivorship : research and practice · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Josefine T DanielsenUnit for Psycho-Oncology and Health Psychology, Department of Psychology and Behavioral Sciences, Aarhus University, Aarhus, Denmark.ORCID https://orcid.org/0000-0002-8249-9700
Robert ZachariaeUnit for Psycho-Oncology and Health Psychology, Department of Psychology and Behavioral Sciences, Aarhus University, Aarhus, Denmark.
Henrik SchmidtDepartment of Oncology, Aarhus University Hospital, Aarhus, Denmark.
Jesper F KallehaugeDanish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark.
Julie K ThomadsenUnit for Psycho-Oncology and Health Psychology, Department of Psychology and Behavioral Sciences, Aarhus University, Aarhus, Denmark.ORCID https://orcid.org/0009-0002-8951-1984
Jeffrey S WefelSection of Neuropsychology, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Lisa M WuUnit for Psycho-Oncology and Health Psychology, Department of Psychology and Behavioral Sciences, Aarhus University, Aarhus, Denmark.
Ali AmidiUnit for Psycho-Oncology and Health Psychology, Department of Psychology and Behavioral Sciences, Aarhus University, Aarhus, Denmark.

Funding

Aase og Ejnar Danielsens Fond 22-10-0063A. P. Moellers Fonden for Laegevidenskabens Fremme FID2014816Dansk Kraeftforskningsfond; Kraeftafdelingens Forskningsfond Aarhus Universitetshospital; Fabrikant Einar Willumsens Mindelegat
6 · The paper itself

Abstract

backgroundCancer-related cognitive impairment (CRCI) is a significant concern in patients with cancer but understanding its prevalence and risk factors in patients with malignant melanoma (MMPs) remains limited. This study explores CRCI via a multifaceted approach integrating neurobiological, genetic, and psychological assessments.

methodsCognitive functioning across multiple domains was assessed via neuropsychological tests in 47 MMPs before adjuvant immune checkpoint inhibitor therapy, compared with 53 matched healthy controls (HCs). Self-reported cognitive complaints, brain gray matter (GM) properties, catechol-O-methyltransferase (COMT) genotype, and psychological and behavioral factors were evaluated. Between-group differences were analyzed with t-tests and χ

resultsMMPs exhibited significantly lower cognitive functioning across multiple tests (all p < .05), with a high CRCI prevalence (68.1% vs. 26.4% in HCs). MMPs reported higher fatigue, anxiety, and insomnia severity and poorer sleep quality and quality of life (all p < .01). Self-reported cognitive complaints in MMPs were associated with some cognitive test scores (all p < .05), fatigue (p < .001), and anxiety (p = .045). GM analyses revealed a smaller left cuneus volume in MMPs and significant associations between MMPs' processing speed and cortical thickness (right precentral and left inferior parietal regions) and between delayed verbal memory and right postcentral GM volume (all p < .01).

conclusionsThese findings underscore the need for comprehensive assessments in MMPs to better understand and address CRCI. A multifaceted approach would provide valuable insights that could inform future interventions and improve patient outcomes and quality of life.

Indexed as

Catechol O-MethyltransferaseCognitive DysfunctionGray MatterImmune Checkpoint InhibitorsMelanomaAdultAgedCase-Control StudiesFemaleGenotypeHumansMagnetic Resonance ImagingMaleMiddle AgedNeuropsychological TestsQuality of LifeCatechol O-MethyltransferaseCOMT protein, humanImmune Checkpoint Inhibitorscancercancer‐related cognitive impairment (CRCI)catechol‐O‐methyltransferase (COMT)magnetic resonance imagingmelanomapsycho‐oncologyside effects

Identifiers

PMID39663713
PMCPMC11733852

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.